Nathalie D. Mckenzie, MD

Nathalie D. Mckenzie , MD

Gynecologic Oncologist

Cancer

Nathalie Mckenzie

Overview

Natalie Dauphin McKenzie, MD, MSPH, is a board-certified gynecologic oncologist with a breadth of experience providing advanced treatments including minimally invasive and robotic-assisted procedures for women with all types of gynecologic cancer. She earned her medical degree with research honors at the University of New York at Buffalo and undertook her residency training and fellowship at the University of Miami/Jackson Memorial Hospital. She also earned her Master of Science in Public Health with honors while completing her fellowship training.

Dr. McKenzie is an award-winning physician who is known for her expertise in radical debulking procedures for removing advanced tumors. She is particularly interested in HPV-related neoplasia and patient-driven cancer treatment. She is also a multilingual provider with fluency in English, French, medical Spanish and Haitian Creole.

Articles

Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

2024

Rapid recurrence of stage IIB non-gestational ovarian choriocarcinoma with minor yolk sac tumor: A rare case report and literature review

GYNECOLOGIC ONCOLOGY REPORTS

2023

Prognostic features of the tumor microenvironment in high-grade serous ovarian cancer and dietary immunomodulation

LIFE SCIENCES

2023

Clinical outcomes analysis of neoadjuvant chemotherapy for locally advanced vulvar cancer

Gynecologic oncology

2023

Analysis of "sandwich" chemo-radiation therapy for stage IIIC endometrial cancer

Gynecologic oncology

2023

Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancer

Gynecologic oncology

2023

Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer The Nonrandomized Phase 2 VIRO-15 Clinical Trial

JAMA ONCOLOGY

2023

Fused Clitoral Hood Presenting as a Periclitoral Mass

OBSTETRICS AND GYNECOLOGY

2022

CERVICAL CANCER TREATED BY NEOADJUVANT CHEMOTHERAPY FOLLOWED BY RADICAL SURGERY: A CASE SERIES FROM MIREBALAIS, HAITI

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

2022

MALIGNANT PERITONEAL CYTOLOGIC CONTAMINATION WITH ROBOTIC HYSTERECTOMY FOR ENDOMETRIAL CANCER

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

2022

More Publication Information

Education & Training

Education

University of New York at Buffalo School of Medicine, Buffalo, NY

Residency

Memorial Sloan Kettering Cancer Center, NY

Fellowship

University of Miami/ Jackson Memorial Hospital, Miami, FL

Specialty

Gynecology Oncology

Board Certifications

American Board of Obstetrics and Gynecology

Associated Clinical Trials

NCT05256225

NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA

Icon for trial | NRG GY026 NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL S

This study is currently enrolling.

This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer quest ...